Skip to main content
NeuroThera Labs Inc. logo

NeuroThera Labs Inc. — Investor Relations & Filings

Ticker · NTLX ISIN · CA64136J1012 LEI · 529900GPL3C0DVADMS32 TSXV Manufacturing
Open in API
Filings indexed 145 across all filing types
Latest filing 2024-05-29 Regulatory Filings
Country CA Canada
Listing TSXV NTLX

About NeuroThera Labs Inc.

https://www.neurothera.com/

NeuroThera Labs Inc. is a clinical-stage company specializing in the development of therapeutics and advanced technologies for central nervous system (CNS) disorders and brain health. The company operates through two primary development streams. First, it is a leader in photobiomodulation (PBM) technology, developing drug-free, non-invasive devices for neurotherapy, targeting conditions such as Major Depressive Disorder (MDD), Alzheimer’s Disease, and Traumatic Brain Injury (TBI). Second, NeuroThera maintains a pharmaceutical pipeline focused on novel drug candidates, including programs based on THC and proprietary opioid/non-opioid compounds designed to enhance pain relief and treat CNS disorders. This dual approach leverages both advanced medical devices and clinical-stage drug candidates to address prevalent neurological conditions.

Recent filings

Filing Released Lang Actions
Audited annual financial statements – English.pdf
Regulatory Filings
2024-05-29 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Capital/Financing Update Classification · 95% confidence The document is a detailed summary of financial securities linked to an index, specifically RBC notes linked to the Solactive Canada Blue Chip AR index. It includes detailed terms and conditions such as duration, interest payments, redemption conditions, and risk factors. The document is a prospectus or offering summary for structured financial products, describing the terms of issuance and investment details. It is not a report of financial results, management discussion, or regulatory filing. It is also not an announcement of a report but a detailed product offering document. This type of document fits best under Capital/Financing Update (CAP), as it relates to the issuance and terms of financial instruments and capital raising products.
2023-12-18 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification statement by the CEO of Miza III Ventures Inc. regarding the review and fair presentation of the interim financial report and interim MD&A for the period ended October 31, 2023. It is a Form 52-109FV2 Venture Issuer Basic Certificate, which is a regulatory certification related to interim filings. The document does not contain actual financial data or substantive financial analysis but is an attestation of the interim filings' accuracy and completeness. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the interim report itself (IR). The document length is short (2947 characters), and it is clearly a certification rather than the report or announcement of a report. Therefore, the correct classification is Regulatory Filings (RNS).
2023-12-18 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate signed by the CFO. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended October 31, 2023. The document is primarily an officer certification letter and does not contain actual financial statements or substantive financial data. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3026 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2023-12-18 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification form (Form 52-109FV2) signed by the CEO certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended October 31, 2023. It explicitly states it is a certification of interim filings for a venture issuer and does not contain the actual financial data or detailed financial statements. The document is primarily an officer certification and attestation rather than the interim report itself. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as an Interim Report (IR). The document length is short (3027 characters), consistent with a certification letter rather than a full report.
2023-12-16 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification statement by the CFO of Miza III Ventures Inc. regarding the interim financial report and interim MD&A for the period ended October 31, 2023. It is a Form 52-109FV2 Venture Issuer Basic Certificate, which is a certification of interim filings. The text explicitly states it is a certification and does not contain the actual interim financial data or analysis itself. According to the CERTIFICATION RULE, such officer certifications should be classified as Regulatory Filings (RNS), not as the interim report (IR) itself. The document length is short (2945 characters), and it is primarily a certification letter rather than the report or announcement of a report. Therefore, the correct classification is Regulatory Filings (RNS).
2023-12-16 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.